KalVista Pharmaceuticals (KALV) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for sebetralstat for symptomatic treatment of acute attacks of hereditary angioedema.
Final decision from the European Commission is expected by early October, the company said.
Hereditary angioedema, or HAE, is a rare, genetic and potentially life-threatening disease that can lead to painful and debilitating attacks of tissue swelling in various locations of the body.
The European regulator based its opinion on the phase 3 clinical trial showing that sebetralstat led to faster symptom relief and reduced attack severity and attack resolution than placebo, with a well-tolerated safety profile similar to placebo, KalVista said.
Sebetralstat is approved in the US and United Kingdom under the brand name Ekterly for treatment of people with HAE 12-years-old and older.
The company's shares were up more than 1% in recent premarket activity Friday.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。